Hospital

The second part of this video series highlights thoughts from 4 panelists on shared clinical decision-making and how harmful misinformation is in the health care space.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid free with good pain ratings and tolerability.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Tanika Kelly, PhD, MPH, discusses her study finding that greater chronic kidney disease (CKD) severity significantly increases the risk of cognitive impairment, with important implications for how pharmacists counsel and support these patients.

A group of experts provide insights and answer questions to some of the more pressing topics around changes in vaccine schedules and policies.

Experts discuss practice expansion, guideline updates, and team-based care.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.